Both GO annotation and KEGG pathway enrichment suggest that andrographolide may have a therapeutic role in CRC through inhibition of cellular growth, proliferation, and migration and induction of apoptosis by targeting the hub genes (PDGFRA, PTGS2, MMP9, MAPK1, and MET) which is involved in cancer migration and invasion. This evidence concerns the gene MET and cancer.